2025-07-31T12:51:38-05:00 2024-12-31 PwC US Tax LLP 655 NEW YORK AVENUE NW SUITE 1100 WASHINGTON DC 20001 990 2024-01-01 473355381 PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY % SARA COBLIN PARK 4159304386 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 KAREN KNUDSEN CEO 4159304386 2025-07-28 true true TRAVIS PATTON P00369623 6464713000 2025-07-25 2024 2025-03-06 01:10:19Z SEAN PARKER 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 67696083 false X WWW.PARKERICI.ORG X 2015 CA SEE SCHEDULE O 16 16 26 18 0 0 1204708 44804456 8658418 2800807 12348436 16986942 1451074 2354964 23662636 66947169 14807382 29715699 0 0 11068299 10443144 0 0 216886 17027670 14312191 42903351 54471034 -19240715 12476135 255027743 223870654 52813770 38432216 202213973 185438438 X THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY'S (PICI) MISSION IS TO ACCELERATE THE DEVELOPMENT OF BREAKTHROUGH IMMUNE THERAPIES TO TURN ALL CANCERS INTO CURABLE DISEASES. false false 49160578 29715699 2800807 PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (PICI) ENCOURAGES ADVANCES IN CANCER IMMUNOTHERAPY RESEARCH, COLLABORATION, AND DISCOVERY, AND THE TRANSLATION OF THESE ADVANCES INTO CURES AND TREATMENTS FOR THE BENEFIT OF PATIENTS. TO DO THIS, PICI PARTNERS WITH ITS CONSORTIUM OF PREEMINENT HOSPITALS AND ACADEMIC RESEARCH CENTERS TO CONDUCT ITS DISCOVERY AND CLINICAL RESEARCH AND PROVIDES ITS PARTNERS WITH SHARED RESEARCH RESOURCES, SUCH AS SCIENTIFIC EQUIPMENT, CONSUMABLES, BIOINFORMATICS ANALYSIS, AND A SPECIMEN BIOBANK. PICI ALSO FUNDS AND OTHERWISE SUPPORTS CANCER IMMUNOTHERAPY RESEARCH WITHIN ITS CONSORTIUM. 49160578 true true false false false false false false false false true true true false true true true false false false true false false false false false false true false true false false false true false false false false false false false false true true true true false false true 37 0 true 26 true false false false false false false false false false false false false X 16 16 true false false false false true true true true false false true true true true true true true true false AL AK AR CA CO CT DC FL GA HI IL KS KY ME MD MA MI MN MS NV NH NJ NM NY NC ND OH OK OR PA RI SC TN VA WA WV WI X SARA COBLIN 6288997600 1 LETTERMAN DRIVE SUITE D3500 SAN FRANCISCO CA 94129 X JOHN CONNOLLY PHD CHIEF SCIENTIFIC OFFICER 40.0 0.0 X 855710 0 71836 KEVIN MARKS CHIEF LEGAL OFFICER 40.0 0.0 X 840863 0 72056 UTE DUGAN MD CHIEF MED. OFFICER THRU 6/24 20.0 0.0 X 715023 0 105296 TARAK MODY CHIEF BUSINESS OFFICER 40.0 0.0 X 632310 0 71836 SHANE CORCORAN SENIOR VP, STRAT. OPS. & COMMS 40.0 0.0 X 669429 0 30971 SARA COBLIN SR VP FINANCE & ADMIN. 40.0 0.0 X 564812 0 49885 MARKO SPASIC SR MEDICAL DIR, HEAD OF MED 40.0 0.0 X 418090 0 9159 CHRISTEN DIPETRILLO HEAD OF INTELLECTUAL PROPERTY 40.0 0.0 X 354287 0 72064 SEAN N PARKER CHAIR OF THE BOARD & DIRECTOR 5.0 5.0 X X 0 0 0 MICHAEL POLANSKY EXECUTIVE VP & DIRECTOR 5.0 5.0 X X 0 0 0 TOM VAN LOBEN SELS TREASURER & DIRECTOR 1.0 0.0 X X 0 0 0 JEFFREY A BLUESTONE PHD VICE CHAIR & DIRECTOR 1.0 0.0 X 0 0 0 TONY COLES MD DIRECTOR 1.0 0.0 X 0 0 0 ERIC ESRAILIAN MD MPH DIRECTOR 1.0 0.0 X 0 0 0 SCOTT GOTTLIEB MD DIRECTOR 1.0 0.0 X 0 0 0 BEN HOROWITZ DIRECTOR 1.0 0.0 X 0 0 0 JEFF HUBER DIRECTOR 1.0 0.0 X 0 0 0 BOB HUGIN DIRECTOR 1.0 0.0 X 0 0 0 REED JOBS DIRECTOR 1.0 0.0 X 0 0 0 BOB NELSEN DIRECTOR 1.0 0.0 X 0 0 0 BRUCE PARKER PHD DIRECTOR 1.0 0.0 X 0 0 0 BOB PITTMAN DIRECTOR 1.0 0.0 X 0 0 0 RAMY IBRAHIM MD DIRECTOR 1.0 0.0 X 0 0 0 MARGO GEORGIADIS DIRECTOR 1.0 0.0 X 0 0 0 SUSAN DAWSON SECRETARY 5.0 5.0 X 0 0 0 5050524 0 483103 24 false true false STANFORD UNIVERSITY PO BOX 419473 BOSTON MA 02241 PATENT & LICENSE EXP 1345434 REGENTS OF UNIV OF CAL SAN FRANC 1111 FRANKLIN STREET 11TH FLOOR OAKLAND CA 94607 PATENT/CLINIC EXP. 1017795 THE TRUSTEES OF THE UNIV OF PA 3451 WALNUT ST 5TH FL FRANKLIN B PHILADELPHIA PA 19104 PATENT/CLINIC EXP. 653093 REGENTS OF UNIV OF CAL LOS ANGEL 1111 FRANKLIN STREET 11TH FLOOR OAKLAND CA 94607 PATENT & LICENSE EXP 548409 UNIV OF TEXAS MD ANDERSON CANCER C 1515 HOLCOMBE BLVD UNIT 1695 HOUSTON TX 77030 CLINICAL TRIAL EXP 454564 22 44804456 44804456 CLINICAL TRIAL & RESEARCH SUPPORT 900099 1900057 1900057 LICENSE FEES 900099 900750 900750 2800807 2439179 2439179 0 2354964 2354964 0 0 0 15296677 748914 14547763 14547763 14547763 0 0 0 0 0 0 0 0 0 0 66947169 2800807 19341906 29713380 29713380 0 2319 2319 0 2455162 1566589 888573 0 0 6430856 4776855 1536824 117177 144827 101404 40889 2534 1018351 722092 274307 21952 393948 262781 125727 5440 0 3758353 3388069 370284 0 379687 0 379687 0 0 0 0 1121393 966379 122114 32900 43970 186 43784 0 109166 40117 68424 625 553669 431652 107937 14080 0 1552760 978239 558993 15528 691437 609121 80645 1671 0 3417334 3415414 1864 56 0 0 0 173581 9815 163766 0 PATENT AND LICENSE EXPENSE 1401350 1401350 0 0 CLINICAL TRIAL SUPPORT 571499 571499 0 0 BIO BANKING 90130 90130 0 0 RECRUITING 280243 0 280243 0 167619 113187 49509 4923 54471034 49160578 5093570 216886 3286878 682163 65585234 27944828 0 0 4756494 2356768 764842 713816 0 0 0 0 0 0 2651610 2610092 9001522 8706522 255000 295000 0 0 23331587 51705196 151742635 136078266 0 0 2653463 1484525 255027743 223870654 7199228 7876148 0 0 875000 0 0 0 0 0 7000000 0 0 0 0 0 37739542 30556068 52813770 38432216 X 194119787 174101042 8094186 11337396 202213973 185438438 255027743 223870654 X 12476135 -29251670 X false true X true false X MEMORIAL SLOAN KETTERING CANCER CENTER NEW YORK NY UNIVERSITY OF TEXAS MD ANDERSON CANCER CENT HOUSTON TX UNIVERSITY OF CALIFORNIA LOS ANGELES LOS ANGELES CA UNIVERSITY OF CALIFORNIA SAN FRANCISCO SAN FRANCISCO CA UNIVERSITY OF PENNSYLVANIA PHILADELPHIA PA DANA-FARBER CANCER INSTITUTE BOSTON MA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI NEW YORK NY FRED HUTCHINSON CANCER RESEARCH CENTER ST LOUIS MO WEILL CORNELL MEDICINE NEW YORK NY BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE DUARTE CA WASHINGTON UNIVERSITY IN ST LOUIS ST LOUIS MO CHILDREN'S HOSPITAL OF PHILADELPHIA PHILADELPHIA PA UNIVERSITY OF PITTSBURGH PITTSBURGH PA UNIVERSITY OF SOUTHERN CALIFORNIA LOS ANGELES CA CURIE INSTITUTE PARIS FR STANFORD MEDICINE STANFORD CA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 720271 720271 0 0 0 0 8281251 7986251 295000 295000 ARSENAL BIOSCIENCES 25001565 F 3T BIOSCINECES 1530855 F GEORGIAMUNE INC. 23186078 F APRICITY HEALTH, LLC 232281 F SENTI BIOSCIENCES, INC. 87750 F XAIRA THERAPEUTICS 1666667 F 51705196 IMAGINAB 1004281 F DISPATCH BIO 30596726 F MOONLIGHT BIO 9700000 F AKAMIS 626106 F LYELL IMMUNOPHARMA,INC 4662248 F AFFINI-T THERAPEUTICS 21611968 F TWAIN 5000000 F ARSENAL BIOSCIENCES 53619294 F 3T BIOSCIENCES 6104167 F KIIK THERAPEUTICS 3153476 F 136078266 0 CONDITIONAL CONTRIBUTIONS 29000000 LEASE LIABILITY 1556068 30556068 X 38015499 -29251670 320000 -28931670 66947169 66947169 54791034 320000 320000 54471034 54471034 PART X, LINE 2: PICI HAS NO UNRECOGNIZED TAX BENEFITS OR LIABILITIES AS OF DECEMBER 31, 2024 AND 2023. true Europe (Including Iceland and Greenland) 0 0 Program Services SERVICES&SPONSORSHIPS 15660 Europe (Including Iceland and Greenland) 0 0 Investments 626106 East Asia and the Pacific 0 0 Program Services RESEARCH SERVICES 1275 East Asia and the Pacific 0 0 Investments 5000000 Europe (Including Iceland and Greenland) 0 0 Grantmaking 2319 Europe (Including Iceland and Greenland) 0 0 Program Services SCIENTIFIC RETREAT 9377 0 0 0 0 5654737 5654737 false false true false false false PART I, LINE 2 PICI AWARDS GRANTS SUBJECT TO A MASTER COLLABORATION AGREEMENT AND A SPECIFIC GRANT AGREEMENT SUBJECT TO EACH INSTITUTION. EACH INSTITUTION SUBMITS PROJECT PROPOSALS WHICH ARE EVALUATED TO ENSURE THEY ARE WITHIN THE CHARITABLE MISSION BEFORE APPROVAL. ALSO, EACH INSTITUTION AND GRANT RECIPIENT MUST PROVIDE PICI WITH ANNUAL REPORTS OF PROJECT PROGRESS AND ASSOCIATED SPEND. PART I, LINE 3, NUMBERS (2) AND (4) EACH OF THESE INVESTMENTS ARE PROGRAM-RELATED INVESTMENTS OF PICI. PICI INVESTS IN COMPANIES TO ACCELERATE FACILITATING THE DEVELOPMENT OF NOVEL CANCER THERAPIES. EACH INVESTMENT COMPANY MUST PROVIDE QUARTERLY FINANCIALS AND PICI IS REPRESENTED ON THE BOARD OF DIRECTORS FOR ONE OF THE INVESTMENTS. RESEARCH SPONSORSHIP WAS ALIGNED WITH THE COMPANY MISSION AND THE REMAINING IMMATERIAL SPEND WAS WITH VENDORS TO SUPPORT CLINICAL TRIALS AND EMPLOYEE DEVELOPMENT. PART I, LINE 3 ACCRUAL BASIS true BECKMAN RESEARCH INSTITUTE OF CITY OF HOPE 1500 E DUARTE ROADE DUARTE CA 91010 953435919 501(C)(3) 333333 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVENUE BOSTON MA 21115 042263040 501(C)(3) 5425000 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY FHCRC - HUTCHINSON 1100 FAIRVIEW AVE N SEATTLE WA 98109 237156071 501(C)(3) 999377 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY ICAHN SCHOOL OF MEDICINE ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 28755 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVE BOX 69 NEW YORK NY 10065 912154267 501(C)(3) 167500 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY STANFORD UNIVERSITY 3145 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 3582836 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY THE J DAVID GLADSTONE INSTITUTES 1650 OWENS STREET SAN FRANCISCO CA 94158 237203666 501(C)(3) 2685423 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY REGENTS OF THE UNIVERSITY OF CALIFORNIA 10920 WILSHIRE BLVD LOS ANGELES CA 90024 956006143 GOVT 750146 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN 333 CALIFORNIA ST SAN FRANCISCO CA 94143 946036493 GOVT 3099545 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1400 PRESSLER STREET HOUSTON TX 77030 746001118 501(C)(3) 377267 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA PA 19104 231352685 GOVT 4666368 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY UNIVERSITY OF PITTSBURGH 420 FIFTH AVENUE PITTSBURGH PA 15260 260965591 501(C)(3) 256241 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY UNIVERSITY OF SOUTHERN CALIFORNIA 3500 S FIGUEROA LOS ANGELES CA 900898001 951642394 501(C)(3) 122117 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY WASHINGTON UNIVERSITY IN ST LOUIS 700 ROSEDALE AVE SAINT LOUIS MO 63112 430653611 GOVT 623478 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY WEILL CORNELL MEDICINE 1300 YORK AVENUE NEW YORK NY 10065 131623978 501(C)(3) 4977086 SUPPORT RESEARCH IN FIELD OF CANCER IMMUNOTHERAPY 15 0 PART I, LINE 2: PICI AWARDS GRANTS SUBJECT TO A MAIN COLLABORATION AGREEMENT AND A SPECIFIC GRANT AGREEMENT SUBJECT TO EACH INSTITUTION. PICI AND EACH INSTITUTION JOINTLY REVIEW AND APPROVE PROJECT PROPOSALS TO ENSURE THEY HAVE A LEGITIMATE RESEARCH PURPOSE AND ARE WITHIN THE CHARITABLE MISSION BEFORE APPROVAL. ALSO, EACH INSTITUTION AND GRANT RECIPIENT MUST PROVIDE PICI WITH ANNUAL REPORTS OF PROJECT PROGRESS AND ASSOCIATED SPEND. X true true X X X X true false false false false false false true false JOHN CONNOLLY PHD CHIEF SCIENTIFIC OFFICER 595290 0 179400 0 81020 0 10350 0 61486 0 927546 0 0 0 KEVIN MARKS CHIEF LEGAL OFFICER 599693 0 240000 0 1170 0 10350 0 61706 0 912919 0 60000 0 UTE DUGAN MD CHIEF MED. OFFICER THRU 6/24 350030 0 184770 0 180223 0 10350 0 94946 0 820319 0 0 0 SHANE CORCORAN SENIOR VP, STRAT. OPS. & COMMS 429670 0 129800 0 109959 0 10350 0 20621 0 700400 0 0 0 TARAK MODY CHIEF BUSINESS OFFICER 485040 0 146100 0 1170 0 10350 0 61486 0 704146 0 0 0 SARA COBLIN SR VP FINANCE & ADMIN. 433842 0 129800 0 1170 0 10350 0 39535 0 614697 0 0 0 MARKO SPASIC SR MEDICAL DIR, HEAD OF MED 379020 0 37900 0 1170 0 0 0 9159 0 427249 0 0 0 CHRISTEN DIPETRILLO HEAD OF INTELLECTUAL PROPERTY 321017 0 32100 0 1170 0 10350 0 61714 0 426351 0 0 0 PART I, LINE 1A ANYONE TRAVELING OVER 3000 MILES CAN FLY BUSINESS CLASS OR FIRST CLASS (IF ONLY 2 LEVELS OF SERVICE ARE OFFERED). VP'S CAN TRAVEL BUSINESS OR FIRST CLASS FOR TRAVEL OVER 2000 MILES. PART I, LINE 3 THE CHIEF EXECUTIVE OFFICER POSITION WAS VACANT DURING 2024. THE ORGANIZATION FOLLOWS THE FOLLOWING PROCEDURES IN DETERMINING SUCH COMPENSATION: THE BOARD OF DIRECTORS OR EXECUTIVE COMMITTEE REVIEWS ANY PROPOSED COMPENSATION, INCLUDING THE SALARY, OF ITS CHIEF EXECUTIVE OFFICER TO ENSURE THAT, IN EACH CASE, SUCH SALARY IS FAIR AND REASONABLE BASED ON COMPARABILITY DATA AND COMPENSATION STUDIES SHOWING COMPENSATION PAID FOR COMPARABLE SERVICES AT SIMILARLY SITUATED ORGANIZATIONS. PART I, LINE 4A UTE DUGAN RECEIVED A SEVERANCE PAYMENT OF $179,638. PART I, LINE 7 MOST OF PICI'S EMPLOYMENT AGREEMENTS, WHICH ARE NEGOTIATED AT ARMS-LENGTH WITH REFERENCE TO COMPARABILITY DATA, CONTAIN A PROVISION PERMITTING ANNUAL INCENTIVE BONUSES, WHICH ARE CAPPED AT UP TO A FIXED PERCENTAGE. JOHN CONNOLLY PHD EMPLOYEE HOME LOAN X 750000 713816 false true true 713816 FORM 990, PART I, LINE 1 DESCRIPTION OF ORGANIZATION MISSION: THE PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY (PICI) IS A SAN FRANCISCO-BASED NONPROFIT WHICH HAS ESTABLISHED COLLABORATION BETWEEN THE COUNTRY'S LEADING IMMUNOTHERAPY RESEARCHERS AND CANCER CENTERS, INCLUDING STANFORD UNIVERSITY; THE UNIVERSITY OF CALIFORNIA, LOS ANGELES; THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO; THE UNIVERSITY OF PENNSYLVANIA; DANA FARBER CANCER INSTITUTE; AND GLADSTONE INSTITUTES. PICI ALSO SUPPORTS TOP RESEARCHERS AT OTHER INSTITUTIONS, INCLUDING CITY OF HOPE; FRED HUTCHINSON CANCER RESEARCH CENTER; ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI; INSTITUTE FOR SYSTEMS BIOLOGY; MEMORIAL SLOAN KETTERING CANCER CENTER; THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER; WEILL CORNELL MEDICAL COLLEGE; AND WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS. BY FORGING ALLIANCES WITH ACADEMIC, INDUSTRY, AND NONPROFIT PARTNERS PICI SUPPORTS NOVEL RESEARCH TO FULFILL ITS MISSION: TO ACCELERATE THE DEVELOPMENT OF BREAKTHROUGH IMMUNE THERAPIES TO TRANSFORM ALL CANCERS INTO CURABLE DISEASES. FORM 990, PART VI, SECTION A, LINE 1 THE BOARD OF DIRECTORS IS COMPRISED OF ONE 'CLASS A' DIRECTOR WITH THE BALANCE OF THE DIRECTORS SERVING AS 'CLASS B' DIRECTORS. THE CLASS A DIRECTOR MUST BE PRESENT TO CONSTITUTE A QUORUM, UNLESS THE CLASS A DIRECTOR'S RECUSAL IS REQUIRED BY LAW OR CORPORATE POLICY. EACH DIRECTOR IS ENTITLED TO ONE VOTE. ANY ACT OF THE BOARD OF DIRECTORS REQUIRES THE AFFIRMATIVE VOTE OF BOTH THE CLASS A DIRECTOR AND A MAJORITY OF THE CLASS B DIRECTORS PRESENT AT A MEETING AT WHICH A QUORUM IS PRESENT, EXCEPT AS OTHERWISE PROVIDED IN THE BYLAWS. PICI DOES HAVE AN EXECUTIVE COMMITTEE. IT HAS ALL THE AUTHORITY OF THE BOARD OF DIRECTORS BETWEEN REGULAR AND SPECIAL MEETINGS, EXCEPT AS OTHERWISE PROVIDED IN THE BYLAWS OR BY THE BOARD OF DIRECTORS IN SPECIFIC INSTANCES. ACTIONS OF THE EXECUTIVE COMMITTEE ARE REPORTED TO AND REVIEWED BY THE BOARD OF DIRECTORS AT ITS NEXT REGULARLY SCHEDULED MEETING. FORM 990, PART VI, SECTION A, LINE 2 THE FOLLOWING DIRECTORS, KEY EMPLOYEES, AND OFFICERS HAVE A BUSINESS RELATIONSHIP AND/OR FAMILY RELATIONSHIP: JOHN CONNOLLY, SUSAN DAWSON, ERIC ESRAILIAN, SCOTT GOTTLIEB, BEN HOROWITZ, JEFF HUBER, REED JOBS, BOB NELSEN, BRUCE PARKER, SEAN PARKER, BOB PITTMAN, MICHAEL POLANSKY, TOM VAN LOBEN SELS. FORM 990, PART VI, SECTION A, LINE 7A THE DESIGNATOR HAS THE AUTHORITY TO APPOINT MEMBERS OF PICI'S GOVERNING BODY. FORM 990, PART VI, SECTION A, LINE 7B THE DESIGNATOR HAS THE AUTHORITY TO REMOVE MEMBERS OF PICI'S GOVERNING BODY, TO CONSENT TO SUCH REMOVAL BY THE BOARD, AND TO CONSENT TO ANY AMENDMENTS TO PICI'S BYLAWS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS REVIEWED BY THE AUDIT COMMITTEE. A COMPLETE COPY OF THE FORM 990 AND SUPPORTING SCHEDULES WAS PROVIDED TO THE FULL BOARD FOR REVIEW PRIOR TO BEING FILED WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD AUTHORIZES AND OVERSEES A REVIEW OF THE ADMINISTRATION OF THE CONFLICT OF INTEREST POLICY. THE REVIEW CONSIDERS THE LEVEL OF COMPLIANCE WITH THE POLICY, THE CONTINUING SUITABILITY OF THE POLICY, AND WHETHER THE POLICY SHOULD BE MODIFIED AND IMPROVED. IF A TRANSACTION ARISES WHERE THERE IS A CONFLICT OF INTEREST, THE PERSON WITH SUCH CONFLICT IS NOT ALLOWED TO VOTE ON THE TRANSACTION NOR BE PRESENT FOR SUCH VOTE. THE CONFLICT OF INTEREST POLICY COVERS EACH DIRECTOR, CORPORATE OFFICER, TOP MANAGEMENT OFFICIAL, TOP FINANCIAL OFFICIAL AND EACH KEY EMPLOYEE OF PICI, AND OTHERS THAT PICI MAY IDENTIFY. FORM 990, PART VI, SECTION B, LINE 15 FORM 990, PART VI, SECTION B, LINE 15A - AS STATED AT SCHEDULE J, PART I, LINE 3, THE CEO POSITION WAS VACANT DURING THE 2024 CALENDAR YEAR. THE ORGANIZATION FOLLOWS THE FOLLOWING PROCEDURES: THE BOARD OF DIRECTORS APPROVES THE SALARY OF PICI'S CHIEF EXECUTIVE OFFICER ONLY AFTER HAVING CONFIRMED IT IS FAIR AND REASONABLE BASED ON COMPARABILITY DATA AND COMPENSATION STUDIES SHOWING COMPENSATION PAID FOR COMPARABLE SERVICES AT SIMILARLY SITUATED ORGANIZATIONS. FORM 990, PART VI, SECTION B, LINE 15B THE ORGANIZATION DOES NOT COMPENSATE ITS CORPORATE OFFICERS, BUT ADHERES TO THE FOLLOWING PROCEDURES FOR ITS KEY EMPLOYEES: THE BOARD OF DIRECTORS (OR DULY AUTHORIZED AND INDEPENDENT BOARD COMMITTEE) APPROVES THE SALARY OF PICI'S KEY EMPLOYEES ONLY AFTER HAVING CONFIRMED IT IS FAIR AND REASONABLE BASED ON COMPARABILITY DATA AND COMPENSATION STUDIES SHOWING COMPENSATION PAID FOR COMPARABLE SERVICES AT SIMILARLY SITUATION ORGANIZATIONS. FOR ITS OTHER EMPLOYEES, PICI UTILIZES THE SERVICES OF AN INDEPENDENT HR CONSULTANT AS WELL AS RELEVANT COMPENSATION DATABASES TO COMPARE ANY PROPOSED SALARIES WITH SALARIES PAID BY OTHER ORGANIZATIONS FOR SIMILAR POSITIONS. FORM 990, PART VI, SECTION C, LINE 19 PICI'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE MADE AVAILABLE AS REQUIRED BY LAW. MAVERIC LLC 1 LETTERMAN DRIVE D3500 SAN FRANCISCO CA 94129 853467441 COVID-19 CLIN CA 0 PICI SEAN N PARKER FOUNDATION 314 LYTTON AVE PALTO ALTO CA 94301 274389819 NONPROFIT SUP CA 501(C)(3) PF PICI true ECONOMIC INNOVATION GROUP INC 616 H STREET NW SUITE 550 WASHINGTON DC 20001 462450336 PUBLIC INTERE DC 501(C)(4) N/A PICI true PARATOPE INC 1 LETTERMAN DRIVE SUITE D3500 SAN FRANCISCO CA 94129 992858074 SOCIAL WELFAR CA 501(C)(4) N/A PICI true false false false false false false false false false false false false false false false false false true false SEAN N PARKER FOUNDATION R 6000000 CASH VALUE PART I, IDENTIFICATION OF DISREGARDED ENTITIES: NAME OF DISREGARDED ENTITY: MAVERIC, LLC ADDRESS: 1 LETTERMAN DRIVE, D3500 SAN FRANCISCO, CA 94129 EIN: 85-3467441 PRIMARY ACTIVITY: COVID-19 CLINICAL TRIAL MANAGEMENT (CURRENTLY INACTIVE) DIRECT CONTROLLING ENTITY: PARKER INSTITUTE FOR CANCER IMMUNOTHERAPY SCHEDULE R, SUPPLEMENTAL INFORMATION: THE CLASS A DIRECTOR ALSO HAS A CONTROLLING INTEREST IN SEVERAL PASSIVE INVESTMENT VEHICLES. THESE INVESTMENT VEHICLES AND THE TAX-EXEMPT ENTITIES DISCLOSED UNDER PART II ABOVE MAY TECHNICALLY BE CONSIDERED "RELATED ORGANIZATIONS" OF PICI FOR IRS FORM 990 REPORTING PURPOSES THROUGH THEIR RELATIONSHIP WITH THE CLASS A DIRECTOR. THE PASSIVE INVESTMENT VEHICLES HAVE NO TRANSACTIONS OR BUSINESS RELATIONSHIPS WITH PICI AND ARE NOT DISCLOSED ON SCHEDULE R.